Limits...
Detection of Serum Protein Biomarkers for the Diagnosis and Staging of Hepatoblastoma.

Zhao W, Li J, Zhang J, Gao P, Pei H, Wang L, Guo F, Yu J, Zheng S, Wang J - Int J Mol Sci (2015)

Bottom Line: Although the expression level decreased with increasing disease stage, pair-wise comparison revealed significant differences in Apo A-I expression between the normal group and the HB subgroups (p < 0.01).ELISA verified the reduced expression of Apo A-I in the HB group.Taken together, these results suggest that Apo A-I may represent a serum protein biomarker of HB.

View Article: PubMed Central - PubMed

Affiliation: Department of Pediatric Surgery, the First Affiliated Hospital of Zhengzhou University, Jianshe Road, Zhengzhou 450000, China. 13460300188@163.com.

ABSTRACT
The present study aimed to identify serum biomarkers for the detection of hepatoblastoma (HB). Serum samples were collected from 71 HB patients (stage I, n = 19; stage II, n = 19, stage III, n = 19; and stage IV, n = 14) and 23 age- and sex-matched healthy children. Differential expression of serum protein markers were screened using surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF-MS), and the target proteins were isolated and purified using HPLC and identified using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF-MS), SEQUEST, and bioinformatics analysis. Differential protein expression was confirmed by enzyme-linked immunosorbent analysis (ELISA). SELDI-TOF-MS screening identified a differentially expressed protein with an m/z of 9348 Da, which was subsequently identified as Apo A-I; its expression was significantly lower in the HB group as compared to the normal control group (1546.67 ± 757.81 vs. 3359.21 ± 999.36, respectively; p < 0.01). Although the expression level decreased with increasing disease stage, pair-wise comparison revealed significant differences in Apo A-I expression between the normal group and the HB subgroups (p < 0.01). ELISA verified the reduced expression of Apo A-I in the HB group. Taken together, these results suggest that Apo A-I may represent a serum protein biomarker of HB. Further studies will assess the value of using Apo A-I expression for HB diagnosis and staging.

No MeSH data available.


Related in: MedlinePlus

2D-LC-LTQ-MS analysis of peptide segments obtained by enzymatic hydrolysis of the proteins or peptide segments with an m/z of 9348 Da.
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4490467&req=5

ijms-16-12669-f005: 2D-LC-LTQ-MS analysis of peptide segments obtained by enzymatic hydrolysis of the proteins or peptide segments with an m/z of 9348 Da.

Mentions: The protein sample with an m/z of 9348 Da was digested, and the Peptide mass fingerprints (PMFs) of the target protein was obtained using two-dimensional liquid-chromatography linear-trap-quadrupole mass-spectrometry (2D-LC-LTQ-MS) (Figure 5). After the amino acid sequences of the various protein fragments were obtained (Table 3), they were recombined to obtain a complete amino acid sequence (Table 4). Analysis of the sequence using the SEQUEST program and the Bioworks database identified Apolipoprotein A–I (Apo A–I) with a matching rate of 45.0% and a matching score of 88 points.


Detection of Serum Protein Biomarkers for the Diagnosis and Staging of Hepatoblastoma.

Zhao W, Li J, Zhang J, Gao P, Pei H, Wang L, Guo F, Yu J, Zheng S, Wang J - Int J Mol Sci (2015)

2D-LC-LTQ-MS analysis of peptide segments obtained by enzymatic hydrolysis of the proteins or peptide segments with an m/z of 9348 Da.
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4490467&req=5

ijms-16-12669-f005: 2D-LC-LTQ-MS analysis of peptide segments obtained by enzymatic hydrolysis of the proteins or peptide segments with an m/z of 9348 Da.
Mentions: The protein sample with an m/z of 9348 Da was digested, and the Peptide mass fingerprints (PMFs) of the target protein was obtained using two-dimensional liquid-chromatography linear-trap-quadrupole mass-spectrometry (2D-LC-LTQ-MS) (Figure 5). After the amino acid sequences of the various protein fragments were obtained (Table 3), they were recombined to obtain a complete amino acid sequence (Table 4). Analysis of the sequence using the SEQUEST program and the Bioworks database identified Apolipoprotein A–I (Apo A–I) with a matching rate of 45.0% and a matching score of 88 points.

Bottom Line: Although the expression level decreased with increasing disease stage, pair-wise comparison revealed significant differences in Apo A-I expression between the normal group and the HB subgroups (p < 0.01).ELISA verified the reduced expression of Apo A-I in the HB group.Taken together, these results suggest that Apo A-I may represent a serum protein biomarker of HB.

View Article: PubMed Central - PubMed

Affiliation: Department of Pediatric Surgery, the First Affiliated Hospital of Zhengzhou University, Jianshe Road, Zhengzhou 450000, China. 13460300188@163.com.

ABSTRACT
The present study aimed to identify serum biomarkers for the detection of hepatoblastoma (HB). Serum samples were collected from 71 HB patients (stage I, n = 19; stage II, n = 19, stage III, n = 19; and stage IV, n = 14) and 23 age- and sex-matched healthy children. Differential expression of serum protein markers were screened using surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF-MS), and the target proteins were isolated and purified using HPLC and identified using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF-MS), SEQUEST, and bioinformatics analysis. Differential protein expression was confirmed by enzyme-linked immunosorbent analysis (ELISA). SELDI-TOF-MS screening identified a differentially expressed protein with an m/z of 9348 Da, which was subsequently identified as Apo A-I; its expression was significantly lower in the HB group as compared to the normal control group (1546.67 ± 757.81 vs. 3359.21 ± 999.36, respectively; p < 0.01). Although the expression level decreased with increasing disease stage, pair-wise comparison revealed significant differences in Apo A-I expression between the normal group and the HB subgroups (p < 0.01). ELISA verified the reduced expression of Apo A-I in the HB group. Taken together, these results suggest that Apo A-I may represent a serum protein biomarker of HB. Further studies will assess the value of using Apo A-I expression for HB diagnosis and staging.

No MeSH data available.


Related in: MedlinePlus